ReviewFrontiers in medicine2023
Updates in SJS/TEN: collaboration, innovation, and community.
Open access · goldAbstract readReview
In one paragraph
Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Clinicopathologic and Immunohistochemical Features of Enfortumab Vedotin-Induced Cutaneous Toxicity.International journal of dermatology · 2026Article
- New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report.Clinical and translational allergy · 2026Review
- Carbamazepine-induced Stevens-Johnson syndrome in Chinese with negative HLA-A*3101 and HLA-B*1502 genes: A case report.Biomedical reports · 2026Article
- The Outcomes of SJS/TEN: A Nationwide Analysis.Journal of burn care & research : official publication of the American Burn Association · 2026Article
- Evaluation of drug causality in SJS/TEN: The role of the lymphocyte transformation test and conventional/modified IFN-γ ELISpot assays.The World Allergy Organization journal · 2026Article
- JAK inhibitors in toxic epidermal necrolysis a new frontier in therapeutics.Annals of medicine and surgery (2012) · 2026Article
- Immunological and Inflammatory Characteristics of Severe Cutaneous Adverse Drug Reactions: A Retrospective Study.International journal of general medicine · 2026Article
- Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions.European journal of human genetics : EJHG · 2026Review
- Stevens-Johnson syndrome as the presenting manifestation of human immunodeficiency virus and syphilis coinfection.Dermatology online journal · 2025Article
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.Biomedicines · 2025Review
- Improving Recruitment Through Social Media and Web-Based Advertising to Evaluate the Genetic Risk and Long-Term Complications in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Community-Based Survey.Journal of medical Internet research · 2025Article
- Drug allergy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Review
- Etoricoxib and its hidden risks: a case-based review of dermatological, hematological, and cardiovascular complications.EXCLI journal · 2025Review
- Predictive value of a severity-of-illness score for toxic epidermal necrolysis (SCORTEN) factors for in-hospital mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis.Frontiers in medicine · 2025Article
- Clinicopathological Characteristics of Lichenoid Drug Eruption: A 17-Year Retrospective Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Severe Hypersensitivity Reactions with Oral Manifestations: Case Reports on Stevens-Johnson Syndrome and DRESS Syndrome.Journal of pharmacy & bioallied sciences · 2024Article
- Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management.American journal of clinical dermatology · 2024Review
- Article
- Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Analysis of the Russian Database of Spontaneous Reports.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors at 20 institutions in 11 countries.
Madeline E MarksCenter for Drug Interactions and Immunology, Division of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Ramya Krishna BottaCenter for Drug Interactions and Immunology, Division of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Riichiro AbeDivision of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Thomas M BeachkofskyDepartments of Dermatology and Medicine, Uniformed Services University, Bethesda, MD, United States.
Isabelle BoothmanThe SFI Centre for Research Training in Genomics Data Science, Dublin, Ireland.
Bruce C CarletonDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia and the British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
Wen-Hung ChungDepartment of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Ricardo R CibottiNational Institute of Arthritis and Musculoskeletal and Skin (NIAMS), National Institutes of Health (NIH), Bethesda, MD, United States.
Roni P Dodiuk-GadDepartment of Dermatology, Emek Medical Center, Afula, Israel.
Christian GrimsteinOffice of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Akito HasegawaDivision of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Jay H HoofnagleLiver Disease Research Branch, Division of Digestive Diseases and Nutrition of NIDDK, National Institutes of Health (NIH), Bethesda, MD, United States.
Shuen-Iu HungCancer Vaccine and Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Benjamin KaffenbergerDepartment of Dermatology, Ohio State University Wexner Medical Center, Columbus, OH, United States.
Daniela KroshinskyDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Rannakoe J LehloenyaDivision of Dermatology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Michelle Martin-PozoCenter for Drug Interactions and Immunology, Division of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Robert G MichelettiDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Maja MockenhauptDokumentationszentrum schwerer Hautreaktionen (dZh), Department of Dermatology, Medical Center and Medical Faculty, University of Freiburg, Freiburg, Germany.
Keisuke NagaoNational Institute of Arthritis and Musculoskeletal and Skin (NIAMS), National Institutes of Health (NIH), Bethesda, MD, United States.
Suman PakalaCenter for Drug Interactions and Immunology, Division of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Amy PalubinskyCenter for Drug Interactions and Immunology, Division of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Helena B PasiekaDepartments of Dermatology and Medicine, Uniformed Services University, Bethesda, MD, United States.
Jonathan PeterDivision of Allergy and Clinical Immunology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Munir PirmohamedDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Melissa ReyesCenter for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, United States.
Hajirah N SaeedMassachusetts Eye and Ear, Harvard Medical School, Boston, MA, United States.
Jeffery ShuppDepartment of Surgery, Plastic and Reconstructive Surgery, Biochemistry, and Molecular and Cellular Biology, MedStar Washington Hospital Center, Georgetown University School of Medicine, Washington, D.C., DC, United States.
Chonlaphat SukasemDepartment of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Jhih Yu SyuDepartment of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Mayumi UetaDepartment of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Li ZhouDivision of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Wan-Chun ChangDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia and the British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
Patrice BeckerDivision of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Disease, Bethesda, MD, United States.
Teresa BellonDrug Hypersensitivity Laboratory, La Paz Health Research Institute (IdiPAZ), Madrid, Spain.
Kemberlee BonnetDepartment of Psychology, Vanderbilt University, Nashville, TN, United States.
Gianpiero CavalleriThe SFI Centre for Research Training in Genomics Data Science, Dublin, Ireland.
James ChodoshUniversity of New Mexico School of Medicine, Albuquerque, NM, United States.
Anna K DewanDepartment of Dermatology, Vanderbilt University Medical Center, Nashville, TN, United States.
Arturo DominguezDepartment of Dermatology and Internal Medicine, UT Southwestern Medical Center, Dallas, TX, United States.
Xinzhong DongDepartment of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Elena EzhkovaDepartment of Cell, Developmental, and Regenerative Biology and Dermatology, Black Family Stem Cell Institute, Mount Sinai School of Medicine, New York, NY, United States.
Esther FuchsDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, United States.
Jennifer GoldmanDivision of Pediatric Infectious Diseases and Clinical Pharmacology, Children's Mercy, Kansas City, MO, United States.
Sonia HimedCollege of Medicine, University of Cincinnati, Cincinnati, OH, United States.
Simon MallalDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Alina MarkovaDepartment of Dermatology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
Kerry McCawleyStevens-Johnson Syndrome Foundation, Westminster, CO, United States.
Allison E NortonDivision of Pediatric Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, United States.
David OstrovDepartment of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, United States.
Michael PhanDivision of Pharmacovigilance-I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Arthur SanfordDivision of Trauma, Surgical Critical Care, and Burns, Loyola University Medical Center, Chicago, IL, United States.
David SchlundtDepartment of Psychology, Vanderbilt University, Nashville, TN, United States.
Daniel SchneiderDepartment of Psychiatry and Surgery, MedStar Washington Hospital Center, Georgetown University School of Medicine, Washington, D.C., DC, United States.
Neil ShearDepartment of Dermatology, Emek Medical Center, Afula, Israel.
Kanade ShinkaiDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, United States.
Eric TkaczykDepartment of Veterans Affairs, Vanderbilt Dermatology Translational Research Clinic (VDTRC.org), Nashville, TN, United States.
Jason A TrubianoDepartment of Infectious Diseases and Medicine, Austin Health, University of Melbourne, Melbourne, VIC, Australia.
Simona VolpiNational Human Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD, United States.
Charles S BouchardDepartment of Opthalmology, Loyola University Medical Center, Chicago, IL, United States.
Sherrie J DivitoDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
Elizabeth J PhillipsCenter for Drug Interactions and Immunology, Division of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Vanderbilt University Medical Center · USVanderbilt University · USBrigham and Women's Hospital · USCenter for Drug Evaluation and Research · USChang Gung Memorial Hospital · TWEmek Medical Center · ILHarvard University · USLoyola University Medical Center · USMedStar Georgetown University Hospital · USNational Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Institutes of Health · USNiigata University · JPUniformed Services University of the Health Sciences · USUniversity of Cape Town · ZAAustin Health · AUBC Children's Hospital · CAChildren's Mercy Hospital · USCornell University · USHospital La Paz Institute for Health Research · ESIcahn School of Medicine at Mount Sinai · US
Funding
NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisU01AI154659 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2020 to 2025
$15.5MSkin Biology and Diseases Resource-based Center at Mount SinaiP30AR079200 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elena Ezhkova · 2021 to 2026
$5.2MToward Understanding the Role of the Polycomb Complex in Skin ControlR01AR069078 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EZHKOVA, ELENA · 2016 to 2024
$4.4MGenetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivorsR01HG010863 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH · 2019 to 2022
$3.1MImmune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study)R01AI152183 · NIAID · UNIVERSITY OF CAPE TOWN · PI MEINTJES, GRAEME AYTON, PHILLIPS, ELIZABETH · 2020 to 2025
$1.6MCSRD VA IK2 CX001785NHGRI NIH HHS R01 HG010863NIAID NIH HHS R01 AI152183NIAID NIH HHS U01 AI154659NIAMS NIH HHS P30 AR079200NIAMS NIH HHS R01 AR069078
Abstract
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a predominantly drug-induced disease, with a mortality rate of 15-20%, that engages the expertise of multiple disciplines: dermatology, allergy, immunology, clinical pharmacology, burn surgery, ophthalmology, urogynecology, and psychiatry. SJS/TEN has an incidence of 1-5/million persons per year in the United States, with even higher rates globally. One of the challenges of SJS/TEN has been developing the research infrastructure and coordination to answer questions capable of transforming clinical care and leading to improved patient outcomes. SJS/TEN 2021, the third research meeting of its kind, was held as a virtual meeting on August 28-29, 2021. The meeting brought together 428 international scientists, in addition to a community of 140 SJS/TEN survivors and family members. The goal of the meeting was to brainstorm strategies to support the continued growth of an international SJS/TEN research network, bridging science and the community. The community workshop section of the meeting focused on eight primary themes: mental health, eye care, SJS/TEN in children, non-drug induced SJS/TEN, long-term health complications, new advances in mechanisms and basic science, managing long-term scarring, considerations for skin of color, and COVID-19 vaccines. The meeting featured several important updates and identified areas of unmet research and clinical need that will be highlighted in this white paper.
Indexed as
body surface areaelectronic medical recordHLA genotypingpharmacogenomicsSCORTENsevere adverse cutaneous drug reactionsStevens-Johnson SyndromeToxic Epidermal Necrolysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.